Smart In-Vitro Diagnostics (IVD) Market Research Report 2023: Artificial Intelligence for IVD Markets - Bringing Diagnostics Into a Mainstream Role in Healthcare - ResearchAndMarkets.com

2023-03-03
Business Wire
诊断试剂
DUBLIN--(BUSINESS WIRE)--The "Smart in Vitro Diagnostics - Artificial Intelligence for IVD Markets by Application, by Technology and by User with Executive and Consultant Guides" report has been added to ResearchAndMarkets.com's offering.
'Smart in Vitro Diagnostics - Artificial Intelligence for IVD Markets by Application, by Technology and by User with Executive and Consultant Guides'
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of United States Medicare Fee Payment Schedules to help understand the new pricing for nucleic acid based tests.
Will Smart Diagnostics replace the physician? Will the power of Artificial Intelligence provide better diagnostics? The market is moving out of a research mode into the clinic. The market is exploding as physicians use all the information they can get to battle disease. While Pharmaceutical Companies see the potential to make nearly any therapy viable. Find out how this new approach to diagnostics will change medical care forever.
Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of many diagnostics continues to fall.
Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.
The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.
Key Topics Covered:
Recent Developments
Vesale Bioscience to Develop AI Phage Therapy Diagnostic Platform
Caris Life Sciences To Use AI and Machine Learning
Numares Health To Develop AI for "Metabolite Constellations"
Sepsis Testing Startup DeepUll to Use AI for Medical Decisions
Viome Life Sciences Raises $67M in Series C Financing For AI Cancer Dx
ADM Diagnostics Wins Grant for Brain Injury Test Development
Paige to Develop New AI-based Pathology Test
Aiforia Gains CE-IVD Mark for AI-Powered Histopathology
Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
Thermo Fisher Introduces Homologous Score for Cancer Profiling
Genomic Test IDs Cancer Cells Early
Caris Life Sciences to Offer Molecular Profiling Services
Geneseeq to Build Lab for Cancer Profiling in Brazil
Genetron Health Adds New Assays to Pipeline
Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
Guardant Health Receives Medicare Coverage for Guardant360 TissueNextT Test
Labcorp, CCORN Partner for Precision Oncology
Celemics, Strand Partner on Integrated Platform for NGS Analysis
Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
Burning Rock Revenues Rise
Caris Life Sciences to Expand Liquid Biopsy Testing
OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
Intermountain and Myriad Combine Test Offering
Illumina, Geneseeq to Offer Cancer Testing Kits in China
Exact Sciences to Offer End-to-End Cancer Testing
Guardant Health Turns to Tumor Tissue Sequencing
Tempus Inks Oncology Testing Collaboration With Bayer
Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
Metastatic Cancer Markers Identified in Clinical WGS Study
Stitch Bio Bets on CRISPR Tech
Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
Progress, Challenges in Liquid Biopsy Reimbursement
Israeli Startup Curesponse Raises $6M
Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
Germline Results Guides Precision Therapy in Advanced Cancer
FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
Labs Reporting Cancer Risk Mutations from Tumor Testing
Users Begin Integrating Genomics Data for Clinical Decision Support
Fujitsu Improves Efficiency in Cancer Genomic Medicine
Market Trends
Factors Driving Growth
Level of Care
Companion Dx
Immuno-oncology
Liability
The Aging Effect
Factors Limiting Growth
State of knowledge
Protocol Resistance
Regulation and coverage
Instrumentation, Automation and Diagnostic Trends
Traditional Automation and Centralization
The New Automation, Decentralization and Point Of Care
Instruments Key to Market Share
Bioinformatics Plays a Role
PCR Takes Command
Next Generation Sequencing Fuels a Revolution
NGS Impact on Pricing
Whole Genome Sequencing, A Brave New World
Companion Diagnostics Blurs Diagnosis and Treatment
Shifting Role of Diagnostics
Market Overview
Players in a Dynamic Market
Academic Research Lab
Diagnostic Test Developer
Instrumentation Supplier
Chemical/Reagent Supplier
Pathology Supplier
Independent Clinical Laboratory
Public National/regional Laboratory
Hospital Laboratory
Physicians Office Lab (POLS)
Audit Body
Certification Body
Oncogenomics
Carcinogenesis
Chromosomes, Genes and Epigenetics
Chromosomes
Genes
Epigenetics
Cancer Genes
Germline vs Somatic
Gene Panels, Single Gene Assays and Multiplexing
Genomic Profiling
The Comprehensive Assay
Changing Clinical Role
The Cancer Screening Market Opportunity
Cancer Management vs. Diagnosis
The Role of Risk Assessment
Diagnosis
Managing
Monitoring
Phases of Adoption - Looking into The Future
Structure of Industry Plays a Part
Hospital Testing Share
Economies of Scale
Hospital vs. Central Lab
Physician Office Lab's
Physician's and POCT
Profiles of Key Players
Agilent/Dako
Anchor Dx
Baylor Miraca Genetics Laboratories
BioIVT
Bioview
Bolidics
Burning Rock
Celemics
CellMax Life
Cepheid (Danaher)
Circulogene
Clinical Genomics
Cytolumina Technologies Corp.
GILUPI Nanomedizin
Guardant Health
HansaBiomed
HeiScreen
Helomics
iCellate
Incell Dx
Invivoscribe
Millipore Sigma
Myriad Genetics/Myriad RBM
NGeneBio
Novogene Bioinformatics Technology Co., Ltd.
Oncocyte
OncoDNA
Perkin Elmer
Personalis
Promega
Rarecells SAS
RareCyte
Sense Biodetection
Siemens Healthineers
simfo GmbH
Singulomics
Standard BioTools
Veracyte
Volition
Standard BioTools
Sure Genomics, Inc.
Volition
For more information about this report visit https://www.researchandmarkets.com/r/8m0z1f-in-vitro?w=4-in-vitro?w=4-in-vitro?w=4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。